Merck licenses antidepressant candidate to Cerecor

04/22/2013 | Pharmaceutical Business Review Online

Merck & Co. granted Cerecor exclusive global rights to develop and market the experimental drug MK-0657, a small molecule NMDA receptor subunit 2B antagonist for all clinical indications. Cerecor plans to develop the compound as a treatment for severe refractory depression and suicidal thoughts and behavior. The deal entitles Merck to milestone fees and royalties.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA